GRCEGrace Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Grace Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRCEEsta | $44M#4 | — | 0.9x#1 | 0.4x#1 | — | 18.6%#3 | -11.1%#5 | -16.2%#3 | — | — | -32.4%#5 | — |
| GLMD | $30M#5 | — | 2.4x#2 | — | — | -37.1%#6 | — | -80.9%#4 | — | — | -60.7%#6 | — |
| GMAB | — | — | — | — | 19.2%#1 | -15.0%#4 | 28.6%#1 | — | — | — | 23.8%#3 | — |
| GNMSF | — | — | — | — | 19.2%#1 | -15.0%#4 | 28.6%#1 | — | — | — | — | — |
| GSK | $216.6B#1 | — | — | — | — | — | — | — | — | — | 24.6%#2 | — |
| HCM | $12.0B#2 | 26.4x#1 | 9.7x#3 | 21.8x#2 | -13.0%#3 | 1111.0%#1 | -7.1%#3 | 36.9%#1 | 0.0%#1 | — | -21.5%#4 | — |
| HELP | $267M#3 | — | — | — | — | — | — | — | — | — | 106.3%#1 | — |
| HMDCF | — | — | — | — | -13.0%#3 | 1111.0%#1 | -7.1%#3 | 36.9%#1 | 0.0%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice